Big Week Ahead For Stocks… And Emergent’s Mpox Approval 8/30/24

30 Aug 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Notes: CNBC's "Fast Money" Episode - Big Week Ahead For Stocks… And Emergent’s Mpox Approval (8/30/24)

Episode Overview

  • Host: Contessa Brewer (in for Melissa Lee)
  • Focus: Recap of August trading, market expectations for September, and discussions on key stocks including Emergent BioSolutions after receiving FDA approval for its Mpox vaccine.

---

Key Topics Discussed

  1. Market Performance in August
  2. Stock Recovery: After a rough start, stocks managed to rebound significantly, with the S&P rallying over 10% from the lows of August 5.
  3. Index Performance: All three major indexes (S&P, Dow, Nasdaq) reported gains for the month, marking four consecutive months of increases for the S&P and Dow.
  1. August to September Transition
  2. Concerns for September: Traditionally a challenging month for stocks, with multiple catalysts on the horizon:
  3. Upcoming jobs report.
  4. Anticipation for Apple's new iPhone launch.
  5. Federal Reserve's decision on interest rates.
  1. Expectations from the Federal Reserve
  2. Focus on Fed Actions: The Fed's move on interest rates is critical. Predictions lean towards a 25 basis point cut, with upcoming jobs data likely influencing future decisions.
  3. Market Sentiment: Discussions highlighted that the market has largely priced in these expectations, reducing the likelihood of unexpected Fed actions.
  1. Jobs Report Impact
  2. Importance of Payroll Numbers: Market reactions are highly sensitive to employment data, with discussions about the labor market's health and implications for Fed policy.

---

Stock-Specific Discussions

  1. Emergent BioSolutions and Mpox Vaccine
  2. FDA Approval: Emergent received FDA approval for its smallpox vaccine to treat Mpox, but the stock experienced a notable decline post-approval, closing down nearly 7%.
  3. Market Reaction: Discussion on the potential addressable market for the vaccine, especially in developing countries, and the challenges in quantifying financial impact.
  1. Trends in Biotech and Other Sectors
  2. Intel's Struggles: Analysis of Intel's ongoing issues and its strategic options to revive its struggling business.
  3. Alibaba's Recovery: Discussion on Alibaba's regulatory challenges and its recent bounce-back following a lengthy compliance process.
  1. Consumer Sector Insights
  2. Retail Earnings: Mixed earnings reports from retailers, showcasing a challenging environment with rising competition and changing consumer behavior.
  3. Ulta Beauty: Notable drop in Ulta’s stock after missing earnings estimates, attributed to intense competition and rising inventories.

---

Key Takeaways

  • Market Outlook: The ability of the stock market to maintain its upward trajectory into September is uncertain, given historical trends and upcoming economic data.
  • Fed Influence: The Federal Reserve's decisions are critical in shaping market expectations and should be closely monitored by investors.
  • Emergent's Vaccine Impact: While the approval is a positive development for Emergent, market interpretation reflects caution regarding the actual financial benefits.
  • Consumer Spending Concerns: Retail sector performance indicates potential weakness in consumer spending, which could have broader economic implications.

---

Final Thoughts The episode illustrates the complex interplay of various factors influencing the stock market as it transitions from August to September, with a strong emphasis on upcoming economic data and sector-specific performance. Key stocks like Emergent BioSolutions and major market players such as Intel and Alibaba remain focal points for investors navigating this turbulent landscape.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02From the Nasdaq market side in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. Stocks rallying to close out trading for the month of August, but with fall just around the corner, sorry to say, what's going to drive the market into the fall? From the jobs report next week to a looming Fed decision, we get you the playbook for the next few months. And insuring gains. Shares of companies like Allstate and Progressive trading at all-time highs. But is there more juice left in their run? We break out the technicals to find out. Plus, Intel says it's looking at ways to revive its struggling business.

0:40Alibaba clears a three-year-long regulatory battle and why approval of Emergent Bio's Mpox vaccine wasn't enough to lift the stock. We have all those stories coming up this hour. I'm Contessa Brewer in for Melissa Lee. Coming to you live from Studio B at the NASDAQ, on the desk tonight we have Steve Grasso, Tim Seymour, Carter Wirth, and Mike Coe. And we start with an August to remember for stocks. After a stunning stumble to start the month, markets rebounded in a big way. The S &P rallying in today's close and now more than 10 percent higher than the lows hit on August 5th. And less than half a percent of its all-time highs hit six weeks ago.

1:23All three major indexes manage gains for the month, with the S &P and the Dow now up four months in a row. Now attention turns to September, traditionally one of the worst months for stocks and a slew of new potential catalysts for the market. From next week's jobs report to the next iPhone launch party to that closely watched Fed decision toward the end of the month. And which of these events will you watch most closely? I'll start with you, Steve. Yeah, I think it has to be the Fed, right? We got through NVIDIA. That was the biggest thing that we could all focus on was NVIDIA. But it's always NVIDIA or the Fed.

2:00And now Apple kind of sneaks in there. You guys have been doing a lot of coverage on that on the network. AI, I have an iPhone 13. This is going to be a powerful upgrade cycle. I'm going to upgrade. Not that I need all the new fancy stuff. I usually upgrade. What do most people upgrade for? Because they want the new gadgets that are on the phone. The camera, right? So this one's going to be AI. Yep. And AI and the camera. and who knows what else, a host of other things that are going to be available. I believe it's going to be the Fed. The Fed is the biggest thing that we have to focus on. Although, interestingly, we seem to all be on the same page with what the Fed is going to do to cut rates.

2:42You don't think that there's going to be any surprises from the Fed, that they're not going to overshoot it by half a basis point? Oh, I think that it's going to be 25 basis points. I don't think that there's a case to be made to make it a half a point. Unless, you know, it just will be very uncharacteristic of Jay Powell to just pull a half a point out of the hat right now. I think it'll be 25 basis points and then two more to follow that 75 basis points total. Tim, we have other data coming out next week. All attention paid on that big jobs report that we're expecting next Friday. Which of these do you think moves the needle?

3:16Will it be jobs? Will it be the Fed? Is it that Apple event? You're moving the needle with us today, Contessa. great to have you. And I think it's the payroll number. I really do. And it's not that a weak payroll number will signal that the labor market is caving and collapsing. I just think that the market reaction we got at the last payroll number and the close scrutiny, at least of really look, and the Fed has more or less said that now they are really pushing more towards at least evaluating the labor market and seeing where that side of their two pronged approach is something they may be spending more time on.

3:54So today's PCE number, to me, I think cements the fact that we're at 25 bips. I don't think there's a 50 coming. I don't think there should be a 50 coming. If you look at July consumer spending, it was up about 4.5 % so far, which is more or less kind of where things have been. We haven't seen the consumer fall out of bed. We're going to talk later on in the show about certain segments within retail that I think are under some pressure here. But it's been an extraordinary month. And if you think about some of the tensions we had earlier in the month. I still think the market will digest those.

4:23But as it relates to the Fed, hey, look, that two year to start of June was at five percent. It's now in the three 90s. This is a case where the market has done a lot of the Fed's work for him. I don't think there are surprises here. Mike Coe, twice in one week. It's a lot for me. Nice to see you. Which of these pushes forward for you? Yeah, I mean, look, the payroll number is basically how you're going to judge basically the magnitude and pace of Fed action. So I think both Tim and Steve are right on that. I mean, you don't fight the Fed. We know that rule. But what guides the Fed is going to be things like inflation and payrolls.

4:58And next week, it's payroll. So I think we can't ignore it for that reason. And look, Apple is certainly going to be meaningful as well. It's 7 % of the S &P. And that's sort of the benchmark that we look at when we're trying to gauge the market's health and performance. But the thing that concerns me here a little bit, I have to say, just looking a little bit further on is that as we see the front end of the curve come down, you know, we often talk about issues related to recession and things like that. But as the yield curve goes from an inverted state, you know, out of that, that's oftentimes when the first sort of cracks that we see in the recession actually come to light.

5:32So, you know, I think we could have some of that coming up as well. And Carter? Of all those choices? Thank you. Or more if you want Or other choices. There's always. Right. Speaking to Apple, look, we know that its relative performance peaked two years ago in September of 2022 to its brethren, if you will, its sector, the S &P 500 technology sector. I don't suspect it is all that important, despite its heavy weighting in the market. What we know is that the market has returned to the scene of the crime. The S &P dropped 9.71 percent and has recovered exactly back to that high of July 16th, basically almost two months ago.

6:14So do we break out or don't we? And is it some piece of news, some of the items that you suggested that would cause it? Or do we continue to coil here? My hunch is that we back and fill a bit more and we don't have a big week next week. Well, except for the jobs report. And given what we saw happen in August with the jobs report, there does seem to be a lot of attention paid to that. And because jobs and immigration are taking such a lot of the talking points from the candidates at this stage in the campaign cycle, even more pressure outside of the financial world on jobs and who's doing well and who's not.

6:53I want to ask about CPI here for a minute, because what we got from PCE today, Steve, was kind of a meh. It was expected. It seems to show that we were even, Stephen, CPI next month is we're going to be looking back at August. And again, the consumer having such a big impact on these the stocks that we're seeing, but also giving us a picture of the economy in general. Yeah. And CPI and just expenses. You have to you have to look at where the rates component rate to live in a home or an apartment. What that's considered of a third of it, basically. So we've seen inflation go from nine all the way down to sub three or around three.

7:35And the Fed has indicated that they're going to be on a loosening Fed policy right now. So it would have to be a blowout number to the upside, which no one expects it to be, to really have them change their stance. They've indicated they're ready to cut. They're going to cut. I don't think we're going to have any surprises on the inflation front. And if we do have a one-off here, a one-off there, rates are going – inflation is going down. Rates are going down. The markets have already spoken. They've done a lot of the heavy lifting around the Fed. The Fed just needs to pull the trigger. We had such a wild ride in August in the markets and now heading into September.

8:14And I feel like on CNBC, there should be like a little asterisk that says, you know, past performance, future results and all of that. But Carter, how do you look at seasonality when we are trying to brace for what's to come? Sure. I mean, that's an important factor. And there are all sorts of it's called data mining. Right. Once it is in an election year or how do you do if the first six months are very, very good? What does that imply for the backup? You can get any data series to sort of make one's case. bear or bull. But we do know that seasonality, August is particularly poor, as is September and into October.

8:48Okay, so even though the Dow closed at another record high, our next guest is warning that he's seeing some recession indicators flashing red. David Rosenberg runs Rosenberg Research. I want you to really dive deep into the specifics here, David, because as we said, PCE came in where it's expected. You've got unemployment holding steady at 4.3 percent. You have some earnings reports that have surprised at the upside, even if stock performance has failed to follow suit. So where are you seeing warnings? Well, for one thing, you're talking about earnings for the last quarter, which is in the rearview mirror.

9:27It's interesting to me that you're seeing the stock market go up. and yet earnings estimates for the rest of the year have actually started to come down over the course of the past couple of months and there's been no change from the analysts for 2025 so this has been purely multiple expansion related and you mentioned the consumer and yeah the consumer is really exceeding expectations there's no doubt about it but we have this wide divide right now that's really incredible because real personal disposable income after tax income in real terms is growing 1 % over the past year, and you have real consumer spending running almost 3 % over the past year.

10:08So the follow-up from that is we're seeing this relentless decline in the personal savings rate. I mean, this time last year, the savings rate was already pretty low at 4.5%. Today, it's 2.9%. It's only been this low in the past 5 % of the time. It's a 1 in 20 event. So I look at the consumer, I know what you're saying, but it's really the consumer spending report I would say is a low quality report because it's not being generated by real income growth. It's been generated by a continued drawdown on the savings rate to historically low levels and when we talk about the recession we've seen recession in real capital spending.

10:45The industrial sector is in recession and the housing market is rolled back in a recession. These aren't the biggest components of GDP of course that's the consumer but there are segments of the economy that are operating below the zero line. Admittedly not the consumer dot dot dot not yet. As for your comment on the unemployment rate you know it's not stable at all. It's gone up 80 basis points in the past year and that's what's caught the eye of Jay Powell. That's the only reason why they're cutting interest rates is they're concerned now that there's too much slack being built up in the jobs market.

11:20So that's the story is that you're You're not seeing job loss, but the unemployment rate is going up. And Powell's already told us that is the most important statistic for him right now. So, David, do you think that the Fed is behind the curve on this? Or do you think that this was unavoidable? Just a two-pronged answer. And do you think that the recession, whether we're in one now or there's one that's coming, do you think that it's a first quarter next year issue or a fourth quarter this year? Well, it's a no-brainer that the Fed's behind the curve and the yield curve, speaking of curves, have been telling you that for quite a while.

12:00But Jay Powell told us that both at the last press conference after the July meeting and then last week at Jackson Hole, when he's talking about how the economy is normalized, inflation is normalized to a very large extent, And the labor market is not just normalized, but there's more slack in the labor market now than it was before COVID. So is he behind the curve? Well, you know, everything is normal except the Fed funds rate. And the Fed's own admission in terms of where its guesstimate of where neutral is, is 2.75%. That is the normal interest rate for normalized economy. And the normalized economy is what the Fed's talking about.

12:43And they've got the funds rate of 5.38%. percent. So recession or not, of course, they're behind the curve. Hey, David, it's Tim. Thanks for joining us. Yeah, I guess I shared that view and I share your view, at least that recession proof your term sectors or places at least to be thinking about. It's fascinating that it's a year where you've had a bit of a barbell already. I mean, there certainly has been a very defensive play to the market. If you look at what's been going on with gold, what's been going on with with health care, certainly what's going on with utilities. How do you characterize what you do from here on out?

13:18Because based upon the moves we've had in some of those defensive spaces, that's telling you, it certainly is a read on some of the things you're thinking. Have we missed the move in some of these sectors that are not terribly cheap at this point? Well, of course, what happens in those defensive sectors is that they get re-rated when investors start to see the economy cooling off. And the economy is cooling off. It's not in recession right now. And I think the consensus is that it's not going to go under recession. But, you know, we have the supply side of the economy expanding over 4 percent and GDP, which is what we all focus on, let's assume it's running at two and a half to three.

13:55That's what I'm talking about is we're building up disinflationary slack in the economy. So I think what's happening here is that interest rates have been coming down. The Fed hasn't cut yet, but market rate and they will continue to come down. So I would say that certainly the rate sensitive sectors in this environment get re-rated with a higher multiple and I expect that that's going to continue. What I call the bonds and drag, you mentioned utilities, which of course has defensive growth characteristics too. Bonds and drag in the stock market, so whether you're talking REITs or telecom services, utilities, yes, I think that they're very appropriate right now and being re-rated appropriately because of the industry outlook.

14:35David, thank you for joining us, sharing your thoughts and your perspective with us. Mike, jump in. Are you positioning for recession? Well, I mean, I think there's two questions here. One is, you know, whether or not we think that a recession could still be on the horizon, despite the fact that a lot of people think that, you know, are sort of articulating this soft or no landing thesis. You know, one of the things that David didn't mention this time, but he has certainly spoken about it in the past, is the concept of sort of a corporate debt maturity wall of, give or take,$7 trillion. And the fact that the refinancing rate on that was high was one of the things that was keeping CapEx down.

15:14And so that obviously is going to slow industrial growth, meaningful or real industrial growth. And that, of course, is one part of the problem. The second question, of course, I think for investors is really, what does that mean for the stock market, though? And for that, I'm actually looking less at whether or not I think the potential for recession is there but just what the market is doing day to day. And what it's doing day to day is moving more violently than it historically does. You know, we have a 30-day realized volatility around 19%. That's a lot higher than average. And that actually is a warning sign all its own.

15:47Meanwhile, we've been watching Al and Bobby's shares today jumping after China's market regulators said that the tech giant completed a three-year rectification process and is now compliant with antitrust policies. Baba had been fined the equivalent of$2.6 billion in 2021 as part of the investigation, which accused the company of forcing merchants to choose between two e-commerce platforms rather than work with both. Let's talk about Alibaba here, Steve. Yeah, whenever you're dealing with the Chinese government and stock performance, if you look at the long-term chart of Alibaba, it's horrendous.

16:24So if you go back and you look it through the last couple of months, it looks okay. We're up 7.5 % year to date in Alibaba. Maybe the Chinese government had given us the all clear, but they could renege on that all clear pretty quickly. So if you're going to be long it, you should probably keep it on a short leash. But I do think you're due for a bounce more than the 7.5 % that we've seen this year. And we've heard it from retail companies and their earnings reports even this week, Tim, that the concern over the Chinese consumer is real. How much does that play into even the decision by the Chinese government on Alibaba?

17:03Well, I've been most more concerned about the Chinese government as it relates to Alibaba. And you look at this announcement by Samer. This is the state market regulator. I mean, that to me is a reset. I think it's a new lease on life. I think if you look at the chart on this stock going back the three years that we got these rectifications that came out, You can see a stock that's down almost 65 percent. I mean, Alibaba has been destroyed. And I don't think it's really been about the Chinese consumer. I think it's all been about a discount rate that's had to be raised to the roof. The risk around the company.

17:34I mean, look, we had our weekend at Bernie's moment for Jack Ma. We really never knew what happened to him. We were concerned that there was a lot more going on here. I actually think this is great news. I'm long Alibaba. People who watch the show know I've been long Alibaba for a long time. I mean, I've traded around the stock, but for the most part, this is the kind of news you want to hear. Add into the fact that earlier, actually, it was probably a week ago, they also completed the dual registration in Hong Kong. So the dual listing now, I think, does provide more liquidity. I care about the Chinese consumer.

18:05I like the fact, though, that the valuation here doesn't really need to worry about the strength or lack thereof in the Chinese consumer. And if anything, it's in Alibaba's share price. Forty percent of the market cap is in cash. And I like that. And those shares up 2.8 % today. All right, coming up, another update for Intel, the chipmaker fielding strategic options from the big banks as it looks to address its recent woes. Is this the beginning of a real turnaround? Chapter two, we'll debate that next. And an ugly day for Ulta Beauty investors hammering this consumer favorite after an earnings report that was anything but glamorous.

18:43How badly does this stock need a makeover? Closer look right after this. You're watching Fast Money here on CNBC. We'll be right back.

19:03Welcome back to Fast Money. Intel shares topping the tape today, locking in their best day since October 2022 on news that the chipmaker is in talks with bankers, including Morgan Stanley, to address weakness in its core business. Earlier this month, Intel announced it would lay off 15 ,000 workers during a disastrous earnings report. That sent shares plunging. The stock is down more than five. Is that 50 percent? Yes. This year. Wow. Carter, what do you make of it? Right. So the key, the data point that you cited, of course, is that plunge on earnings, right? You traded 300 million shares that day.

19:43That was August 2nd, essentially dropping from 30 to 20. We spent the entire month of August going absolutely dead flat. So a massive re-rating and then a tight consolidation now on 177 million shares. You're talking about a stock that's average daily volume of 50. A big thrust higher with a gap. What I would do is sell puts, which is to say the news today confirms those lows as decent intermediate lows. I think you can collect premium here, and that's how I'd play it. Just getting long because they want to address their weakness in their core business. They've had a weakness in their core business for a long time, and talking to Goldman Sachs or any other banker is not going to change that.

20:22But it is a big day in the market, and I would become an insurance company and sell premium to someone else. Hmm. Yeah, this is a company that's really chased everyone in the space. They've they've underperformed everyone in the semiconductor space. NVIDIA. Forget about just NVIDIA. You name a semiconductor, they've underperformed it. Even AMD, which is flat, basically. Intel has been the IBM of the semiconductor space where it just seems that they can't move the ship around too much. They're not nimble. I mean, they said today, oh, we're doing this because it's really important that we're super nimble and flexible.

20:58and can adjust quickly. Yeah, too little, too late. And the market's not going to believe it until the market believes it. But to Carter's point, maybe you've got to play it that way instead of buying into the equity because the equity has disappointed you repeatedly. Tim. Well, it's interesting that these headlines, which are the kind of headlines that when I hear about restructuring, and we've put this in the context of a company that is cutting 15 ,000 jobs, et cetera. I mean, people, you know, it's not about solvency per se, but these aren't headlines that necessarily would be driving a stock up 9 percent.

21:33I mean, it almost feels like the activist investor day. It feels like a day where, you know, you get some sense that they're and they say this about markets, too, right? That, you know, markets don't rallying, don't start rallying in the middle of a big downturn until policymakers start panicking. And it does feel as if that there's a little bit of that going on at Intel. So the headlines are interesting. We have nothing concrete. How much do you think this is about Pat Gelsinger's leadership or lack thereof? Well, I think in terms of long and, you know, the lag effects that we talk about with regards to the Fed, I mean, the lack of innovation at Intel and the loss of market share is something that had been going on for years before he got there.

22:13I do think it's a dynamic that you can't just turn this around. But again, it's that innovation gap between Intel and its peers. That's part of where the stock is. seeing their market share even stabilized would be seen as a positive. And that's actually what got that stock rallying from the low 30s to the mid and the upper 30s going into that second quarter print that you got some sense that there was stabilization. So I think this is important news. I think Intel has a lot of access. There is M &A around there. There have been a couple private equity deals in terms of some of these foundry stations over in Ireland.

22:46They sold a big piece to Apollo. I think there's more they can do. But right now, yes, it's Gelsinger's let's just say that I think his reputation here and his credibility is certainly something that needs to be proven. We have a lot more to come on Fast. Here's what's coming up next.

23:21Live from the NASDAQ market site in Times Square. We're back right after this.

23:34Welcome back to Fast Money. Buzzkill on Ulta Beauty. The makeup chain store dropped 4 % after missing top and bottom line estimates after the bell yesterday. The stock is just one of many retailers out with earnings this week. Nordstrom, Abercrombie & Fitch, Gap beat estimates. where Lululemon, American Eagle, Dollar General missed the mark. The sector is having a very mixed earnings season. So is there anything that we can broadly read about consumer behavior right now from the reports of the retailers, Steve? Yeah, those retailers that have really been the wolf on top of the hill, those days are gone.

Read the full transcript

24:15There's too much competition. Lulu sees it with a lot of competition. Alta sees it with a lot of competition. You have a combination with Ulta, with rising inventories, and you have more competitive market. Sephora has been taking market share. Then they try to do a JV with Target. So they're on the defense. There's no offensive push. And we're worried about an economy that's slowing. So people are bargain hunting. So Amazon becomes a competitor. Walmart becomes a competitor. There's a lot of things that are bad. You know, the interesting thing that we take Nordstrom's, for instance, that came out and said, It had great earnings season, but where it's really making hay while the sun shines is in its off-priced Nordstrom rack.

24:59And yet other off-priced labels, if you look at Dollar General, missing. It's not a consistent narrative here. What do you think here? Who wants to jump in, Mike? Yeah, I mean, look, we also saw results from Burlington stores. And, you know, Burlington, I mean, Dollar General is basically the bottom in terms of, you know, the consumer demographic. Burlington is sort of middle and slightly higher. You know, its competition is going to be things like TJX and Ross. And it didn't perform that well on their earnings results. And they were arguably the best grower in the space. You know, they were expecting net ads of about 100 stores over the next couple of years or so.

25:37The whole story speaks to a very weak consumer. And we see that in other places. The savings rate, very low. Net savings, also very low. Consumer debt levels are at all-time highs. and delinquencies are up. You know, you put all these things together and basically 70 percent of the economy is consumers, but a lot of them are struggling. And that's a problem. Carter, do you see a consistent narrative that's emerging in retail? Well, specifically to Ulta, right? If you look at competitors, L 'Oreal, you look at Estee Lauder, you look at Elf, which is one of the best performing stocks in the Russell 3000 hard stop.

26:13They're all under considerable pressure. So So always a mixed bag, right? You had a big move a day ago in Best Buy up, a big move down in Dollar General. That's what stock selection is all about. But specific to the news at Ulta, it is not idiosyncratic. It is the group overall. All right, coming up, an under-the-radar biotech stock with a whiplash reversal after securing FDA approval for its MPOX vaccine. Inside the move and the MPOX treatment market, next. Plus, with insurance stocks near all-time highs, is it too late to add some of this to your portfolio? The chart master says no. The technical tale of this high-flying group right after this.

26:58Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money Podcast. We're back right after this.

27:11Welcome back to Fast Money. Stocks jumping to close out the month of August in positive territory. The Dow gaining 228 points, the S &P popping a full percent, and the Nasdaq surging nearly 200 points. GE Vernova shares also jumped today. Morningstar got really bullish on the name, saying it's positioned to benefit from electrification and decarbonization themes. The energy company also says its recent wind turbine blade incidents, three of them, are not related and that it is continuing to investigate. Shares up 5 % today. Meanwhile, Netflix closing above 700 bucks a share for the first time ever.

27:53Pivotal Research boosted its target for the streaming stock to a new street high of$900. That's about 28 % higher than today's close. Those shares ended 1.3 % higher. Mike, what do you think? Look, I mean, I think Netflix actually is one of the few places that really still does represent growth at a reasonable price. I mean, this thing is basically an unregulated utility. They're winning the streaming wars. They're still growing the top line. They offer a product that everybody wants, needs, uses, and they don't charge a lot for it. They actually have probably arguably some room to even increase prices, I think, in the future.

28:28So, I mean, if you're going to play in the streaming space and everybody's using it, I think Netflix is still the place to be. Emergent BioSolutions secured FDA approval for its smallpox vaccine to be used in people with a high risk of Mpox infection. It's the second vaccine to be cleared to treat Mpox in the U.S. after Danish pharma company Bavarian Nordic got its shot approved in 2019. The stock, which has a market cap of$440 million, had been up more than 20 percent pre-market. But then we saw this big reversal. It closed down nearly 7 percent. Let's get more on the Mpox market with Mizuho health care strategist Jared Holtz.

29:08Jared, good to see you. You too. Thanks for having me. What's the opportunity here for emergent? And to what do you attribute the big turnaround in shares today? Well, I think on the shares, the stock is up a ton this year. I mean, the low for the stock year to date, I think, is around$1.50. So for anyone looking to kind of trade around it, the liquidity it's getting due to this news flow, I think, is probably the biggest driver. and it's allowing traders to sell some strength. Maybe they'll buy it back at some later date. That seems to be fairly common with these vaccine stocks, just given the headline orientation of the names and all the news that's coming along with it.

29:52As far as the opportunity set, I think it's not all that clear. They're going to give a lot of the vaccine away for free. Most of it is going to be going to the developing world, central, eastern Africa. So figuring out the financial impact, I think, is more difficult than the narrative, which I still think is pretty good. And the stock is, you know, as you alluded to, you know, not that much in dollars, 400 million market cap. So there's probably some upside here for sure if they can get this thing right. So, Jared, when you look at this stock, you're touching on all these different key points.

30:26What is the addressable market? Because if no, I don't want to belittle the effects of this disease. But if you do nothing, the recovery rate is between two and four weeks. And we know that vaccines all work in different way, shape and form. Being such a low market cap stock, you spoke about this. Is it just poised because it is such a low market cap stock that it's going to jump all over the place and everyone should just sort of sit on the sidelines? Steve, yeah, that's my my gut here. This is a very tough one to nail down. The population, obviously, you know, when you're when you're talking about an entire continent or a big piece of it is huge.

31:08And there are a lot of reports that this has kind of seeped its way into Europe. Europe's been dealing with it. Continental Europe has been dealing with it for a couple of years now. But the amount of cases are fairly small. You know, this is sort of reminiscent of covid at this stage in the game, whereby you've got a lot of cases. But how severe are they? And based on all the reports that I've read and have kind of like gone through, unless you're immune compromised or have, you know, underlying health conditions, very similar to what we've kind of talked about over the past four years, you're probably OK.

31:42So the addressable market is big. I just really just don't know how the governments are going to pay for it and how much a merchant is going to make off of it. Although demand might be a different story because the difference between MPOX and COVID, and I'm not talking from a medical perspective here, but with COVID, people who were sick didn't look different. People who have MPOX, you can see small children with blisters all over the bodies. Like the emotional reaction, and I hear it from the mom set, is real concern, even though it's not a problem in the United States. but you're hearing parents start to ask about it.

32:21So you have to wonder whether demand is going to outpace what the real relevancy is in terms of medical treatment. Totally agree. I mean, that's the tough thing to kind of decipher in the analyst community is the demand versus the actual severity of MPOX itself. And then tying all that together and kind of putting together a model that makes sense when you've got companies out there that are going to provide the drug for little or no cost for much of the population that's directly impacted. I think the bigger opportunity here might be Europe in time. If patients over there are willing to get the vaccine before they get it or shortly after.

33:06And of course, if we hear of cases in the U.S., It's going to be a stock, you know, EBS is going to be a stock that winds up trading a lot of volume and is going to be very volatile. And at 400 million, I think you've got to take a look at it just because it sounds like we're going to get more cases before we see this thing kind of erode again. So that's kind of, you know, from a from a trading standpoint solely, I think you've got to be long a little bit of the stock here for that. Hey, Jared, it's Tim. Congratulations on beating Forrest Gump in the ping pong championship over there. You know, in addition to being the the Forrest Gump of a pharma strategist, because, in fact, you can talk about so many things.

33:48Let's talk about the week that was for Lilly. Let's talk about a stock that effectively is back to all time highs, despite the fact that we know that there's both competition in the space. And again, we talk about valuations on the show all the time. Just any thoughts on the week that was there? Yeah, it's been an incredible couple of weeks for Lilly. A lot of weakness into the quarter, an absolute monster of a second quarter print. They're doing kind of everything behind the scenes to, you know, take more market share and obesity, to provide the market with a bunch of different options. Now you've got this vial, which is cheaper to manufacture.

34:25It gets to more patients at a cheaper cost. So I think everything they're doing strategically makes sense. Valuations, it continues to be and has been for the past couple of years, is the one kind of not overhang, but the one concern investors have. But I don't really see a lot of valuation sensitivity in the market broadly. So until we kind of see it seep into the market big picture, really not sure why it's going to matter for Lilly. And then on the other hand, you've got the situation where earnings are exploding over the next five years. So Tim, as you keep on moving forward here, the PE multiple gets lower and lower as earnings go higher.

35:01So a lot of investors look at Lillian and they say, OK, yes, very expensive today, but over the long term, not so much. Jared, great to have you. Thank you for joining us. Coming up, insurance stocks are surging this year at nearly 30 percent so far. But can the run last? The chart master gives us the technical take. And the wait is over. This is so exciting. College Football is back. We get into the lineup and what it could mean for sports betting stocks. Fast Money, back in two.

35:39Welcome back to Fast Money. Some insurance stocks claiming gains in August. Names like Allstate and Progressive both up big this month and hitting fresh all-time highs today. Can the good times last? The chart master digging into the technicals to find out. Carter, what do the charts show you about insurance? Sure. Contessa, let's get right to it. A couple different charts to look at. And so first, the weighting. This is an important area of the financial sector, as we know. The S &P 500 Insurance Index, 50 stocks, you see there, 1.3 trillion market cap. And let's look at the top five weightings in that index.

36:15And what, of course, jumps out is Progressive, Chubb, Travelers, and AIG are all property casualty stocks. AFLAC bringing up the rear. Number five is a life insurer. And so let's look at the performance on a comparative basis. And you'll see that here of the iShares insurance ETF versus the XLF, all financials versus the BKX. And what really jumps out on a five-year basis, of course, insurance are 4x the performance of the BKX. Just shows how treacherous an area banks are and also beating the sector. Look at a 10-year comparative chart. And here, too, insurance stocks carrying the day, winning overall.

36:55XLF has things like America Express and Goldman and Berkshire, but handily beating the banks. But in terms of the actual group itself, we can look at two final charts. This is the ETF, IAK, to use if you're going to try to capture this theme. And it's not extended. It recently sold off to trend to its 150-day moving average and bounced. And let's look at this exact same five-year chart, but put some trend lines. We're on our way, I think, to the top of the channel. I think one wants to be long this area of the market. Progressive up 88 % over the last 12 months. We're seeing Chubb up 40%. These are stocks that have really moved.

37:33I just wanted to point out one other interesting note that came out today is that cat bonds. These are catastrophe bonds that usually big institutions buy are up a record amount of a record amount in the last quarter. These are bonds that, you know, they only cost you if a big, very specific weather event happens. And so you've got some of these big institutional players playing here. What do you think, Steve? Yeah, I think you nailed it. We were talking offline about this, about the lag effect with these insurance stocks, where they're taking in all that premium. And if there's no issues that they have to pay out, then the stocks are going to run.

38:13And obviously, it can always flip that lingering lag effect with an insurance name. But the IAK, the number one holding in that is progressive, up 58 percent year to date. That's pulled it up. But that's a great return. I've never really looked at that as an investment until Carter just named it right there. So we just gave you an idea. Thanks, Carter. Mike, weigh in here. What do you think about it? I mean, is insurance an insurance for your portfolio? Well, yeah, I think it is. And I think one of the names you could add, of course, is Berkshire, not just because it's Warren's birthday, but of course, that's one of their sort of predominant areas of business.

38:48It's a low volatility name. They have a huge cash position, so any kind of a pullback they can deploy. I think that's a way to get exposure to the space and a lower volatility way to play it as well. Coming up, a closer look at the top sports betting stocks ahead of a jam-packed weekend of college football. The winners, the losers, and the wild cards next. And speaking of football, don't miss CNBC's official 2024 NFL team valuation starting next Thursday on Squawk Box. More Fast Money in two.

39:25Welcome back to Fast Money. This is the moment many people have been waiting, maybe not all, but most of us. College football is back, baby. The season officially kicking off this weekend and some of the country's biggest D1 programs are hitting the field. The action really highlights a mixed bag for sports betting stocks this year, though. FanDuel parent company Flutter, up nearly 20 percent. But remember, it made the U.S. its primary listing. There was a lot of movement there. DraftKings, just barely negative. Traditional gaming stocks that have sports betting operations like MGM, which is a partner in BetMGM, Caesars, Penn, which now has ESPN Bet.

40:04They're all down double digits in 2024. So not necessarily a touchdown. It's not necessarily a touchdown. When you look at all the charts, the charts, and I'm sure Carter knows these charts like the back of his hand, they all look terrible to me. There's some volatility in a couple of them, but there's a declining trend line on most of these stocks. I always go back to the traditional names, to the Las Vegas, to the MGMs, to a different sort of brick and mortar. And all of them have these sort of online presence as well. But as you cover in depth, a lot of these can't make the money or they can make the money, but it doesn't move the needle as much as the online direct play.

40:50What you're seeing with MGM and with Caesars is a real refocus on the technology. And the hopes that with NFL kicking off on Thursday, that you're going to see their new offerings and the new technology paying off. You know, Tim, it's really interesting because Caesars has the biggest rewards program in the business. MGM can offer its customers go stay at the Bellagio or the Cosmopolitan if these are the rewards that you want to spend. They have something to offer that the giants in sports betting don't have. No question. And, you know, you're Vegas. By the way, you also know that you should take the two and a half points with the Gators this weekend against Miami in the swamp.

41:33And I know that's how you're leaning. I would be. That's just me. I actually like DraftKings here. I acknowledge the chart downtrend, I think, in terms of the pure play in the online sports betting, in terms of the growth in the addressable market. They've been making acquisitions. The acquisition costs in terms of some of their competition have have weighed on margins a bit. They also missed on EBITDA on their recent numbers. But the profitability is there. And that is something that I think at least two years ago we were concerned about and how the rationalization in the space just wasn't happening.

42:05So kind of like DraftKings here and think the trends are solid. Tim, OK, I'm going to hold you to that. We'll see how it is after Super Bowl. Sticking with sports, don't miss CNBC and Boardroom's Game Plan Conference on September 10th in Los Angeles, bringing together athletes, owners, investors, and innovators. I'll be there. I'll be talking sports betting with some of the biggest names in the business. You can scan the QR code or go to CNBCevents.com slash game plan. Up next, your final trades.

42:41Final trade time. Let's go around the horn. Tim, you get the first word. Thank you, Contessa. More clarity at CrowdStrike this week. Stay there. Carter. Rovian Sciences, R-O-I-V, poised to pop. Mike. Up more than 9 % or so. The SEC off those terrible lows. I think he could buy some 30 delta foot. Three seconds, Steve. Walmart. Okay. Thank you for watching Fast Money. Mad Money starts right now. Have a good weekend, everybody. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium.

43:25You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.

From the publisher

August trading is in the books, and after a rough start to the month, stocks managed to rebound. But with a big week on deck, can the bounce back continue? Plus Biotech company Emergent Bio getting FDA approval for its smallpox vaccine to treat mpox. What it could mean for Emergent’s future and the space as a whole. 

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Big Week Ahead For Stocks… And Emergent’s Mpox Approval 8/30/24CNBC's "Fast Money" · 44 min
Listen in VO